Publications by authors named "A Maaroufi"

To assess the impact of the SARS-CoV-2 booster dose on the immune response against COVID-19, we conducted a cross-sectional study in the Casablanca-Settat region of Morocco. The study included 2,802 participants from 16 provinces, all of whom had received three doses of a SARS-CoV-2 vaccine. IgG antibodies targeting the S1 RBD subunit of the SARS-CoV-2 spike protein were quantified using the SARS-CoV-2 IgG II Quant assay and measured on the Abbott Architect i2000SR instrument.

View Article and Find Full Text PDF
Article Synopsis
  • - The study identifies the JN.1 variant of SARS-CoV-2 in Morocco through genomic sequencing.
  • - Four clinical samples were analyzed, including nasopharyngeal swabs from one female and three male patients.
  • - The Illumina COVIDSeq Test was utilized for a thorough genomic analysis of the samples.
View Article and Find Full Text PDF

species, especially and , have been associated with a range of human gastrointestinal diseases. During the last two decades, due to the irrational use of antibiotics in poultry farms, high rates of antimicrobial resistance have been globally reported in and isolates. Recently, acquired linezolid-resistance mechanisms have been reported in spp.

View Article and Find Full Text PDF
Article Synopsis
  • This study examines plasmid-mediated quinolone resistance (PMQR) in bacteria from chickens, their eggs, and poultry farm environments in northeastern Tunisia, analyzing 139 samples.
  • Researchers found high resistance rates against various antibiotics, including a 100% resistance to erythromycin and tetracycline, with all quinolone-resistant strains carrying a specific mutation in the GyrA protein.
  • Additionally, the study identified a new sequence type (ST13450) among eleven isolates and highlights the novel presence of PMQR genes in Tunisia, marking a significant finding in the field.
View Article and Find Full Text PDF

Assessing the prevalence of SARS-CoV-2 IgG positivity through population-based serological surveys is crucial for monitoring COVID-19 vaccination efforts. In this study, we evaluated SARS-CoV-2 IgG positivity within a provincial cohort to understand the magnitude of the humoral response against the SARS-CoV-2 vaccine and to inform evidence-based public health decisions. A community-based cross-sectional seroprevalence study was conducted, involving 10,669 participants who received various vaccines (two doses for BBIBP-CorV/Sinopharm, Covishield vaccine, and Pfizer/BioNTech, and one dose for Johnson & Johnson's Janssen COVID-19 vaccine).

View Article and Find Full Text PDF